Needham & Company LLC Reaffirms Buy Rating for Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix (NASDAQ:OCUL)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a note issued to investors on Tuesday,Benzinga reports. They presently have a $18.00 target price on the biopharmaceutical company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 83.82% from the stock’s current price.

A number of other equities research analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Tuesday, April 21st. Citigroup reissued an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Jefferies Financial Group reissued a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Royal Bank Of Canada reissued an “outperform” rating and issued a $30.00 price target on shares of Ocular Therapeutix in a report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of Ocular Therapeutix in a research note on Monday, April 13th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ocular Therapeutix currently has an average rating of “Moderate Buy” and an average price target of $23.78.

Ocular Therapeutix Price Performance

Shares of Ocular Therapeutix stock traded up $0.08 on Tuesday, hitting $9.79. 493,888 shares of the company traded hands, compared to its average volume of 5,354,751. The firm’s 50-day simple moving average is $9.07 and its 200 day simple moving average is $10.53. The company has a current ratio of 15.39, a quick ratio of 15.32 and a debt-to-equity ratio of 0.11. The company has a market cap of $2.14 billion, a P/E ratio of -6.70 and a beta of 0.93. Ocular Therapeutix has a 12-month low of $6.23 and a 12-month high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. The firm had revenue of $13.25 million for the quarter, compared to analysts’ expectations of $16.13 million. Ocular Therapeutix had a negative net margin of 558.24% and a negative return on equity of 71.22%. The business’s quarterly revenue was down 22.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.29) EPS. Analysts expect that Ocular Therapeutix will post -1.29 earnings per share for the current fiscal year.

Insider Activity at Ocular Therapeutix

In other news, insider Pravin Dugel sold 124,882 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total value of $1,128,933.28. Following the transaction, the insider owned 3,033,078 shares in the company, valued at approximately $27,419,025.12. This represents a 3.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Donald Notman sold 11,446 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $103,471.84. Following the transaction, the chief operating officer directly owned 366,356 shares of the company’s stock, valued at $3,311,858.24. The trade was a 3.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 185,731 shares of company stock worth $1,653,407 over the last 90 days. 2.30% of the stock is currently owned by insiders.

Institutional Trading of Ocular Therapeutix

Large investors have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC boosted its position in shares of Ocular Therapeutix by 124.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,242 shares during the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Ocular Therapeutix during the fourth quarter worth $31,000. Hilton Head Capital Partners LLC boosted its position in shares of Ocular Therapeutix by 30.4% during the first quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,053 shares during the last quarter. Atlas Capital Advisors Inc. bought a new position in shares of Ocular Therapeutix during the fourth quarter worth $61,000. Finally, KBC Group NV bought a new position in shares of Ocular Therapeutix during the fourth quarter worth $78,000. 59.21% of the stock is currently owned by institutional investors.

Ocular Therapeutix News Roundup

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Multiple brokerages reaffirmed bullish ratings and sizable price targets, lifting investor optimism about longer‑term upside: Needham reiterated a Buy with an $18 target (~85% upside from current levels). Needham Buy, $18 PT
• Positive Sentiment: HC Wainwright kept a Buy rating and set a $21 target while publishing FY2027 estimates — the analyst support and higher targets provide positive sentiment for the stock despite mixed fundamentals. HC Wainwright Buy, $21 PT
• Positive Sentiment: Royal Bank of Canada reaffirmed an Outperform with a $30 price target (very large implied upside), which can attract momentum buyers and institutional interest. RBC Outperform, $30 PT
• Neutral Sentiment: Ocular continues advancing its pipeline: the company outlined plans for SOL‑R top‑line timing (Q1 2027) and said it is advancing the AXPAXLI NDA plan — important for long‑term value but timing and binary readouts make near‑term impact uncertain. SOL-R / AXPAXLI update
• Neutral Sentiment: Full Q1 earnings call transcript is available for detail on management commentary and execution plans; useful for investors deciding whether pipeline news offsets near‑term revenue weakness. Q1 2026 earnings call transcript
• Negative Sentiment: Q1 results disappointed: OCUL reported a larger loss and missed revenue estimates (loss $0.41 vs. est. $0.32; revenue below expectations), a near‑term catalyst for selling pressure. Q1 miss reported by Zacks
• Negative Sentiment: Some coverage highlights selling pressure and volatility after the quarter (“nosediving” headlines), reflecting market concern about declining revenue trends and negative margins despite analyst optimism on pipeline. Globe and Mail: Why OCUL is nosediving

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.